<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352271</url>
  </required_header>
  <id_info>
    <org_study_id>MER17MD</org_study_id>
    <nct_id>NCT03352271</nct_id>
  </id_info>
  <brief_title>Individualized Incremental Hemodialysis Study</brief_title>
  <acronym>IIHD</acronym>
  <official_title>Comparison of Clinical Outcomes Between Thrice-weekly and Individualized Incremental Hemodialysis in Incident Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kidney and urology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fasila Hemodialysis Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrice weekly hemodialysis has been the standard of care all-over the world for end-stage
      renal disease (ESRD) requiring renal replacement therapy (RRT). Despite being in the era of
      precision medicine and individualized healthcare, this program doesn't take into account
      patients with residual kidney function (RKF) who don't require a thrice weekly hemodialysis
      frequency. Incremental hemodialysis (defined as twice weekly hemodialysis initiation in
      incident hemodialysis patients with residual kidney function) has been raised as an
      alternative to the conventional thrice weekly dialysis. Retrospective trials has proved
      safety of a twice weekly initiation with comparative efficacy to the thrice weekly program.
      Despite that, there is paucity of prospective observational and rarity of randomized
      controlled trials comparing both regimens. In this study, the investigators tend to provide a
      more individualized incremental hemodialysis approach to incident hemodialysis patients with
      residual urine volume and RKF. The investigators will compare the results to ESRD patients
      initiating a thrice weekly hemodialysis program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to study the feasibility, safety and efficacy of individualized incremental
      (twice weekly, once weekly, once/10days or less frequent) hemodialysis (IIHD) initiation
      versus conventional thrice weekly HD for incident end stage renal disease (ESRD) patients
      with residual urine volume (RUV &lt; 0.5 L/day, as a reference to residual kidney functions) who
      chose hemodialysis as their method of renal replacement therapy (RRT).

      Incremental HD has been an area of research interest in the past few years with many
      publications discussing its feasibility and safety for incident HD patients. Smooth
      transition to dialysis in incident ESRD patients through incremental twice (or even once)
      weekly dialysis initiation has shown benefits in preservation of residual kidney functions
      (RKF) in comparison to thrice weekly HD. It has also been proposed as a method of reducing
      healthcare cost while providing quality healthcare to the patients(1). However, most
      available data are retrospective analysis, few data are present to compare the results to
      thrice weekly HD in a randomized controlled or even in a prospective manner. Incremental HD
      has been also practiced in some parts of Egypt in the last 2-3 years. The investigators will
      compare outcomes of participants starting a less frequent dialysis program to conventional
      thrice weekly HD in a multi-center study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate after 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>To assess and compare Survival rate after 24 months in incident HD patients with individualized incremental HD (IIHD) as an RRT starting regimen, compared to those patients who start RRT with the conventional thrice weekly method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization rate</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of hospital admissions and number of days hospitalized for any cause (including cardiovascular events, CVE) during the 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of residual kidney function</measure>
    <time_frame>24 months</time_frame>
    <description>Preservation of Residual kidney function (time to anuria defined as urine output UOP &lt; 100 ml/day, rate of decline of RKF defined as the slope in decline of daily UOP measured monthly) during the 24 months of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypertrophic cardiomyopathy</measure>
    <time_frame>24 months</time_frame>
    <description>Using Echocardiography to detect the development of hypertrophic cardiomyopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care</measure>
    <time_frame>24 months</time_frame>
    <description>comparing number of hemodialysis sessions in both groups multiplied by the cost of each session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of quality of life (QOL)</measure>
    <time_frame>24 months</time_frame>
    <description>Comparing Quality of life survey values from Kidney Disease Quality of Life short form, KDQOL-SF v1.3, Arabic version between each group members</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia Profile</measure>
    <time_frame>24 months</time_frame>
    <description>Mean hemoglobin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone-mineral metabolism profile</measure>
    <time_frame>24 months</time_frame>
    <description>Mean levels of calcium, phosphorus, parathyroid hormone PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular access complications</measure>
    <time_frame>24 months</time_frame>
    <description>rate of infection, thrombosis and hematoma formation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hemodialysis Complication</condition>
  <condition>ESRD</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Individualized Incremental hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrice weekly dialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ESRD patients initiating a conventional thrice weekly hemodialysis program</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Individualized Incremental hemodialysis</intervention_name>
    <description>Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.</description>
    <arm_group_label>Individualized Incremental hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional thrice weekly hemodialysis</intervention_name>
    <description>Thrice weekly hemodialysis program, the current standard of care for all patients, as a control</description>
    <arm_group_label>Thrice weekly dialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with stage 5 chronic kidney disease (CKD) with estimated glomerular
             filtration rate of less than 10 ml/min/1.73m2 (using CKD-EPI equation for eGFR).

          2. Residual urine volume at least 0.5 L/day or more.

        Exclusion Criteria:

          1. Children &gt; 18 years of age.

          2. Patients who were previously on other types of RRT, either on peritoneal dialysis, or
             on kidney transplant.

          3. Recent (within 3 months) acute kidney injury (AKI).

          4. Urine output less than 0.5 L/day.

          5. Active malignancy at time of inclusion.

          6. Active inflammatory disease with immunosuppressive treatment.

          7. Decompensated Liver disease, Hepatorenal syndrome.

          8. Cardiovascular disease defined as: heart failure type IV of the New York Heart
             Association (NYHA) or Cardiorenal syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed E Elrggal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Sobh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hussein A Sheashaa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed F Elkeraie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed E Elrggal, MD</last_name>
    <phone>+201005038467</phone>
    <email>m_elrgal@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rowan Zyada, MBBCh</last_name>
    <phone>+201153877448</phone>
    <email>rawanzyada@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansourah</city>
        <state>Alexandria</state>
        <zip>21529</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Elrggal, MD</last_name>
      <phone>1005038467</phone>
      <email>m_elrgal@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>kidney and Urology Center</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed E Elrggal, MD</last_name>
      <phone>+201005038467</phone>
      <email>m_elrgal@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Elrggal ME, Zyada R. Gradual initiation of dialysis as a means to reduce cost while providing quality health care. Nat Rev Nephrol. 2017 Nov;13(11):720. doi: 10.1038/nrneph.2017.135. Epub 2017 Sep 25.</citation>
    <PMID>28944775</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Ghahremani-Ghajar M, Obi Y, Kalantar-Zadeh K. Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management. Panminerva Med. 2017 Jun;59(2):188-196. doi: 10.23736/S0031-0808.17.03299-2. Epub 2017 Jan 13. Review.</citation>
    <PMID>28090764</PMID>
  </reference>
  <reference>
    <citation>Obi Y, Streja E, Rhee CM, Ravel V, Amin AN, Cupisti A, Chen J, Mathew AT, Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. Am J Kidney Dis. 2016 Aug;68(2):256-265. doi: 10.1053/j.ajkd.2016.01.008. Epub 2016 Feb 9.</citation>
    <PMID>26867814</PMID>
  </reference>
  <reference>
    <citation>Obi Y, Eriguchi R, Ou SM, Rhee CM, Kalantar-Zadeh K. What Is Known and Unknown About Twice-Weekly Hemodialysis. Blood Purif. 2015;40(4):298-305. doi: 10.1159/000441577. Epub 2015 Nov 17.</citation>
    <PMID>26656764</PMID>
  </reference>
  <reference>
    <citation>Wong J, Vilar E, Davenport A, Farrington K. Incremental haemodialysis. Nephrol Dial Transplant. 2015 Oct;30(10):1639-48. doi: 10.1093/ndt/gfv231. Epub 2015 Jun 1. Review.</citation>
    <PMID>26038351</PMID>
  </reference>
  <reference>
    <citation>Kalantar-Zadeh K, Unruh M, Zager PG, Kovesdy CP, Bargman JM, Chen J, Sankarasubbaiyan S, Shah G, Golper T, Sherman RA, Goldfarb DS. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis. 2014 Aug;64(2):181-6. doi: 10.1053/j.ajkd.2014.04.019. Epub 2014 May 17. Review.</citation>
    <PMID>24840669</PMID>
  </reference>
  <reference>
    <citation>Vanholder R, Van Biesen W, Lameire N. Is starting hemodialysis on a twice-weekly regimen a valid option? Am J Kidney Dis. 2014 Aug;64(2):165-7. doi: 10.1053/j.ajkd.2014.06.003.</citation>
    <PMID>25060001</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Unruh M, Chen J, Kovesdy CP, Zager P, Kalantar-Zadeh K. Infrequent dialysis: a new paradigm for hemodialysis initiation. Semin Dial. 2013 Nov-Dec;26(6):720-7. doi: 10.1111/sdi.12133. Epub 2013 Sep 9. Review.</citation>
    <PMID>24016197</PMID>
  </reference>
  <reference>
    <citation>Libetta C, Esposito P, Dal Canton A. Once-weekly hemodialysis: a single-center experience. Am J Kidney Dis. 2015 Feb;65(2):343. doi: 10.1053/j.ajkd.2014.07.034.</citation>
    <PMID>25616635</PMID>
  </reference>
  <reference>
    <citation>Bieber B, Qian J, Anand S, Yan Y, Chen N, Wang M, Wang M, Zuo L, Hou FF, Pisoni RL, Robinson BM, Ramirez SP. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant. 2014 Sep;29(9):1770-7. doi: 10.1093/ndt/gft472. Epub 2013 Dec 8.</citation>
    <PMID>24322579</PMID>
  </reference>
  <reference>
    <citation>Diao Z, Zhang D, Dai W, Ding J, Zhang A, Liu W. Preservation of residual renal function with limited water removal in hemodialysis patients. Ren Fail. 2011;33(9):875-7. doi: 10.3109/0886022X.2011.605535. Epub 2011 Aug 8.</citation>
    <PMID>21819316</PMID>
  </reference>
  <reference>
    <citation>Elamin S, Abu-Aisha H. Reaching target hemoglobin level and having a functioning arteriovenous fistula significantly improve one year survival in twice weekly hemodialysis. Arab J Nephrol Transplant. 2012 May;5(2):81-6.</citation>
    <PMID>22612193</PMID>
  </reference>
  <reference>
    <citation>Fernández-Lucas M, Teruel-Briones JL, Gomis-Couto A, Villacorta-Pérez J, Quereda-Rodríguez-Navarro C. Maintaining residual renal function in patients on haemodialysis: 5-year experience using a progressively increasing dialysis regimen. Nefrologia. 2012;32(6):767-76. doi: 10.3265/Nefrologia.pre2012.Jul.11517. English, Spanish.</citation>
    <PMID>23169359</PMID>
  </reference>
  <reference>
    <citation>Hanson JA, Hulbert-Shearon TE, Ojo AO, Port FK, Wolfe RA, Agodoa LY, Daugirdas JT. Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol. 1999;19(6):625-33.</citation>
    <PMID>10592355</PMID>
  </reference>
  <reference>
    <citation>Lin X, Yan Y, Ni Z, Gu L, Zhu M, Dai H, Zhang W, Qian J. Clinical outcome of twice-weekly hemodialysis patients in shanghai. Blood Purif. 2012;33(1-3):66-72. doi: 10.1159/000334634. Epub 2011 Dec 29.</citation>
    <PMID>22212562</PMID>
  </reference>
  <reference>
    <citation>Lin YF, Huang JW, Wu MS, Chu TS, Lin SL, Chen YM, Tsai TJ, Wu KD. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton). 2009 Feb;14(1):59-64. doi: 10.1111/j.1440-1797.2008.01016.x. Epub 2008 Nov 19.</citation>
    <PMID>19019171</PMID>
  </reference>
  <reference>
    <citation>Toth-Manikowski SM, Shafi T. Hemodialysis Prescription for Incident Patients: Twice Seems Nice, But Is It Incremental? Am J Kidney Dis. 2016 Aug;68(2):180-183. doi: 10.1053/j.ajkd.2016.04.005.</citation>
    <PMID>27477358</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>February 25, 2018</last_update_submitted>
  <last_update_submitted_qc>February 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Mohamed Elrggal</investigator_full_name>
    <investigator_title>Principle Investigator, Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Incremental hemodialysis</keyword>
  <keyword>Precision medicine</keyword>
  <keyword>Individualized care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

